The frequent activation of the PI3K pathway in many human cancers has led to intensive efforts to identify therapeutic agents that abrogate PI3K signaling and hence these agents may have clinical utility in patients with cancers that have an activated PI3K pathway. This evidence concerns the gene PIK3CB and cancer.